News

News

December 15, 2014

IMMUNOMEDICS REPORTS PRELIMINARY RESULTS FROM PRETARGETED IMAGING STUDY IN PATIENTS WITH METASTATIC BREAST CANCER

December 12, 2014

IMMUNOMEDICS REPORTS EXPANDED PHASE 1/2 TRIALS CONFIRM ACTIVITY AND GOOD SAFETY PROFILE OF SACITUZUMAB GOVITECAN (IMMU-132) IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER

December 4, 2014

IMMUNOMEDICS TO PRESENT AT 25TH ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE

December 3, 2014

IMMUNOMEDICS ANNOUNCES OUTCOME OF 2014 ANNUAL MEETING OF STOCKHOLDERS

November 21, 2014

IMMUNOMEDICS ANNOUNCES ORPHAN DRUG DESIGNATION FOR VELTUZUMAB FOR THE TREATMENT OF PEMPHIGUS

November 20, 2014

IMMUNOMEDICS PRESENTS CLINICAL DATA ON NOVEL ANTIBODY-DRUG CONJUGATES FOR SOLID CANCER THERAPY

November 14, 2014

IMMUNOMEDICS ANNOUNCES SIX PRESENTATIONS ON EPRATUZUMAB IN LUPUS AT LEADING RHEUMATOLOGY MEETING

November 7, 2014

IMMUNOMEDICS RECEIVES THIRD EDISON PATENT AWARD FROM RESEARCH & DEVELOPMENT COUNCIL OF NEW JERSEY

November 5, 2014

IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2015 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

October 29, 2014

IMMUNOMEDICS PROVIDES UPDATE ON PHASE 2 STUDY OF ISACTUZUMAB GOVITECAN IN PATIENTS WITH DIVERSE METASTATIC SOLID CANCERS

October 27, 2014

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST QUARTER FISCAL 2015 FINANCIAL RESULTS

October 22, 2014

IMMUNOMEDICS TO PRESENT UPDATED CLINICAL RESULTS WITH SOLID-TUMOR ANTIBODY-DRUG CONJUGATES AT UPCOMING CONFERENCES

October 20, 2014

IMMUNOMEDICS ANNOUNCES EUROPEAN ORPHAN DRUG DESIGNATION FOR ISACTUZUMAB GOVITECAN FOR PANCREATIC CANCER TREATMENT

October 13, 2014

IMMUNOMEDICS ANNOUNCES PRESENTATIONS AT THE 2014 EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE CONGRESS

September 26, 2014

IMMUNOMEDICS PUBLISHES RESULTS ON IMMUNOTHERAPY OF SOLID CANCERS MEDIATED BY A NOVEL BISPECIFIC ANTIBODY

August 25, 2014

IMMUNOMEDICS ANNOUNCES FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

August 8, 2014

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FOURTH QUARTER AND FISCAL YEAR 2014 FINANCIAL RESULTS

June 9, 2014

IMMUNOMEDICS ANNOUNCES ORPHAN DRUG DESIGNATION FOR IMMU-132 FOR PANCREATIC CANCER THERAPY

June 9, 2014

SCIENTIFIC DATA ON EPRATUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS TO BE PRESENTED AT EULAR 2014

June 2, 2014

IMMUNOMEDICS ANNOUNCES OBJECTIVE RESPONSES IN FIVE TYPES OF SOLID CANCER WITH IMMU-132

June 2, 2014

IMMUNOMEDICS REPORTS IMMU-130 IS ACTIVE IN PATIENTS WITH IRINOTECAN-REFRACTORY COLORECTAL CANCER

June 1, 2014

IMMUNOMEDICS REPORTS DEVELOPMENT OF IMPROVED CANCER IMMUNOTHERAPY AT THE 2014 ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

June 1, 2014

IMMUNOMEDICS REPORTS FINAL EFFICACY RESULTS OF PHASE Ib TRIAL WITH YTTRIUM-90-LABELED CLIVATUZUMAB TETRAXETAN IN PATIENTS WITH METASTATIC PANCREATIC CANCER

May 29, 2014

IMMUNOMEDICS TO PRESENT AT UPCOMING HEALTHCARE CONFERENCES

May 20, 2014

IMMUNOMEDICS REPORTS RESULTS WITH IMMU-132 IN PATIENTS WITH PANCREATIC CANCER

May 19, 2014

IMMUNOMEDICS REPORTS UPDATED RESULTS WITH 90Y-CLIVATUZUMAB TETRAXETAN IN PATIENTS WITH METASTATIC PANCREATIC CANCER

May 15, 2014

IMMUNOMEDICS TO PRESENT UPDATED PHASE II RESULTS FROM ANTIBODY-DRUG CONJUGATE PROGRAMS AT 2014 ASCO

May 13, 2014

IMMUNOMEDICS ANNOUNCES U.S. PATENT FOR IMMU-114

May 7, 2014

IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

May 7, 2014

IMMUNOMEDICS CLOSES $30 MILLION PUBLIC OFFERING OF COMMON STOCK

May 5, 2014

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR THIRD QUARTER FISCAL 2014 FINANCIAL RESULTS

May 2, 2014

IMMUNOMEDICS PRICES $30 MILLION PUBLIC OFFERING OF COMMON STOCK

May 1, 2014

IMMUNOMEDICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

April 23, 2014

IMMUNOMEDICS HIGHLIGHTS CLINICAL PIPELINE FOR SOLID CANCER AND LUPUS THERAPY AT R & D DAY

April 10, 2014

IMMUNOMEDICS TO RING OPENING BELL AND HOST R&D DAY AT THE NASDAQ STOCK MARKET

April 8, 2014

IMMUNOMEDICS REPORTS PRECLINICAL RESULTS ON SN-38 ANTIBODY-DRUG CONJUGATES AS A POTENTIAL NOVEL PLATFORM FOR TREATING CANCER

April 7, 2014

IMMUNOMEDICS REPORTS RESULTS FROM THREE PHASE I TRIALS WITH IMMU-130 IN METASTATIC COLORECTAL CANCER

April 7, 2014

IMMUNOMEDICS ANNOUNCES MULTIPLE PARTIAL RESPONSES WITH IMMU-132 IN SOLID CANCERS

March 31, 2014

IMMUNOMEDICS TO PROVIDE CLINICAL TRIAL UPDATES ON SOLID-TUMOR ANTIBODY-DRUG CONJUGATES AT CANCER CONFERENCE

February 26, 2014

IMMUNOMEDICS EXTENDS PATENT LIFE ON THERAPEUTIC ANTIBODIES

February 26, 2014

IMMUNOMEDICS TO PRESENT AT COWEN AND COMPANY 34TH ANNUAL HEALTH CARE CONFERENCE

February 10, 2014

IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

February 6, 2014

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR SECOND QUARTER FISCAL 2014 FINANCIAL RESULTS

February 4, 2014

IMMUNOMEDICS RANKS 4TH IN THE PATENT BOARD BIOTECHNOLOGY INDUSTRY SCORECARD

January 9, 2014

IMMUNOMEDICS ANNOUNCES INITIATION OF PHASE III CLINICAL TRIAL OF CLIVATUZUMAB TETRAXETAN IN PATIENTS WITH PANCREATIC CANCER